{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.58","upperLimit":"13.7","value":"10.5"},{"groupId":"OG001","lowerLimit":"105","upperLimit":"166","value":"129"},{"groupId":"OG002","lowerLimit":"439","upperLimit":"845","value":"634"},{"groupId":"OG003","lowerLimit":"577","upperLimit":"1200","value":"808"},{"groupId":"OG004","lowerLimit":"6.00","upperLimit":"21.2","value":"13.6"},{"groupId":"OG005","lowerLimit":"9.61","upperLimit":"135","value":"60.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"title":"AUC0-t"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.62","upperLimit":"13.8","value":"10.6"},{"groupId":"OG001","lowerLimit":"116","upperLimit":"166","value":"141"},{"groupId":"OG002","lowerLimit":"618","upperLimit":"845","value":"731"},{"groupId":"OG003","lowerLimit":"577","upperLimit":"1220","value":"811"},{"groupId":"OG004","lowerLimit":"2.91","upperLimit":"6.69","value":"5.01"},{"groupId":"OG005","lowerLimit":"11.7","upperLimit":"65.5","value":"31.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"title":"AUC0-24"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.62","upperLimit":"13.8","value":"10.6"},{"groupId":"OG001","lowerLimit":"116","upperLimit":"166","value":"141"},{"groupId":"OG002","lowerLimit":"618","upperLimit":"846","value":"732"},{"groupId":"OG003","lowerLimit":"578","upperLimit":"1220","value":"813"},{"groupId":"OG005","lowerLimit":"31.4","upperLimit":"31.4","value":"31.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}],"units":"Participants"}],"title":"AUC0-168"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.61","upperLimit":"13.7","value":"10.6"},{"groupId":"OG001","lowerLimit":"116","upperLimit":"166","value":"141"},{"groupId":"OG002","lowerLimit":"618","upperLimit":"846","value":"732"},{"groupId":"OG003","lowerLimit":"578","upperLimit":"1220","value":"814"},{"groupId":"OG005","lowerLimit":"32.5","upperLimit":"32.5","value":"32.5"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"1"}],"units":"Participants"}],"title":"AUC0-inf"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"},{"groupId":"OG005","value":"3"}],"units":"Participants"}],"description":"Area under the plasma concentration curve from time 0 through the last measurable concentration (AUC0-t).\n\nPK samples were obtained from the start of treatment until 72 hours. The AUC0-168 and AUC0-inf were calculated with noncompartmental pharmacokinetic analysis equations.","dispersionType":"Full Range","groups":[{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG000","title":"Cohort 1: N-803 - IV 1 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG001","title":"Cohort 2: N-803 - IV 3 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG002","title":"Cohort 3: N-803 - IV 6 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG003","title":"Cohort 4: N-803 - IV 10 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG004","title":"Cohort 5: N-803 - SQ 10 ug/kg"},{"description":"N-803: Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles","id":"OG005","title":"Cohort 6: N-803 - SQ 15 ug/kg"}],"paramType":"MEAN","populationDescription":"Cohort 7: N-803 - SQ 20 ug/kg did not enroll any subjects In addition, 6 out of 7 SC patients (Cohorts 5 and 6) had insufficient measurable post-tmax sampling to allow for evaluation of the terminal phase-dependent PK parameters (ie, t½, CL/F, Vz/F, AUC0-168, AUC0-∞).","reportingStatus":"POSTED","timeFrame":"Samples were collected and the AUC was determined at 24 hours and at time t (last measurable concentration). The AUC was calculated for 168 hours and time to infinity.","title":"Characterization of the Pharmacokinetic Profile - Area Under the Plasma Concentration Curve","type":"SECONDARY","unitOfMeasure":"hr x ng/mL"}